AXLA

After Chardan Capital and Wedbush gave Axcella Health (NASDAQ: AXLA) a Buy rating last month, the company received another Buy, this time from Noble Financial. Analyst Robert LeBoyer reiterated a Buy rating on Axcella Health today and set a price target of $9.00. The company's shares closed last Tuesday at $2.03. According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 9.7% and a 35.9% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and Ayala Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $10.
https://www.tipranks.com/news/blurbs/axcella-health-axla-received-its-third-buy-in-a-row-4?utm_source=advfn.com&utm_medium=referral